Antriabio Inc (ANTB) 0.9000 $ANTB
AntriaBio Announces $12 Million Private Placement
Marketwire Canada - Wed Jun 29, 7:02AM CDT
LOUISVILLE, CO--(Marketwired - June 29, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $12 million this year in a private placement transaction (the "Transaction". Accredited investors and institutions paid $1.10 for one share of common stock and received warrants exercisable for five years at $1.65 for one share of common stock. The Transaction was led by pH Pharma, an affiliate of SBI Investment Korea ("SBI", Korea's first venture capital firm, which was spun out of SoftBank.
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
Marketwired - Wed Jan 06, 7:30AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that Michael Deperro has joined the Company as Vice President of Operations. In his role reporting directly to the Company's Chief Executive Officer, Mr. Deperro will oversee operations including manufacturing, engineering and facilities.
ALKS: 48.95 (+0.91)
AntriaBio closes first USD2m in private placement
M2 - Fri Dec 11, 4:04AM CST
Biopharmaceutical corporation AntriaBio (Other OTC:ANTB) disclosed on Thursday the completion of the first USD2m under a planned USD15m private placement transaction.
AntriaBio Announces First Close of Private Placement Transaction
Marketwired - Thu Dec 10, 11:50AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it has closed the first $2 million of a planned $15 million private placement transaction (the "Transaction". AntriaBio will use the proceeds from the Transaction for general corporate purposes, including Phase 1 clinical studies for AB101, a once-weekly basal insulin for patients with type 1 and type 2 diabetes.
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
Marketwired - Tue Nov 17, 7:31AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/324,734 titled, "Solvent Extraction From Biodegradable Microparticles." The application covers the methods around solvent extraction and rinse in the manufacturing process for product candidates AB101 and AB301, as well as other internal and external potential pipeline therapies that use AntriaBio's proprietary microsphere drug delivery platform. A Notice of Allowance is a written notification from the USPTO that review of the patent application has completed and issuance of the patent is pending.
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
Marketwired - Wed Sep 16, 6:30AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced the addition of a new product candidate to its product development pipeline.
AntriaBio names David F. Welch PhD to board
M2 - Tue Jun 30, 5:46AM CDT
AntriaBio Inc (OTC:ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced on Monday that it has appointed David F. Welch, PhD to the company's board of directors.
INFN: 11.32 (+0.56)
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
Marketwired - Mon Jun 29, 7:01AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today the appointment of David F. Welch, Ph.D., President and Co-Founder of Infinera Corporation (NASDAQ: INFN), to the Company's Board of Directors. Dr. Welch joins AntriaBio's Board as the Company prepares to conduct clinical studies for its lead product candidate, AB101, a potential once-weekly basal insulin in development for patients with type 1 and type 2 diabetes.
INFN: 11.32 (+0.56)
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
Marketwired - Mon Jun 08, 6:30AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, released preclinical results for its lead product candidate, AB101, at the American Diabetes Association 75th Scientific Sessions® in Boston. The results demonstrated that AB101 has comparable in vitro pharmacology to native insulin, and in two animal species exhibited a prolonged subcutaneous insulin absorption profile, resulting in slow onset, peakless and sustained insulin levels with corresponding glucose reductions, without acute hypoglycemia caused by an insulin burst. These observations occurred at clinically relevant dose projections, demonstrating proof of concept of the potential for AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus.
IPOs & Transactions Week in Review: May 18 - 22 plus "How-to" M&A Webinar Videos
PR Newswire - Tue May 26, 11:20AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Marketwired - Mon May 11, 7:02AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it will be presenting data for its lead product candidate, AB101, on Saturday, June 6, 2015 at the American Diabetes Association 75th Scientific Sessions® in Boston. The abstract, accepted for oral presentation, will include results from preclinical in vitro and in vivo pharmacology studies of AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes.
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Marketwired - Thu Jan 08, 6:35AM CST
AntriaBio, Inc. ("AntriaBio or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board.
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Marketwired - Wed Jan 07, 7:02AM CST
AntriaBio, Inc. ("AntriaBio or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment.
AntriaBio Announces $12 Million Private Placement
Marketwire Canada - Wed Jun 29, 7:02AM CDT
LOUISVILLE, CO--(Marketwired - June 29, 2016) - AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $12 million this year in a private placement transaction (the "Transaction". Accredited investors and institutions paid $1.10 for one share of common stock and received warrants exercisable for five years at $1.65 for one share of common stock. The Transaction was led by pH Pharma, an affiliate of SBI Investment Korea ("SBI", Korea's first venture capital firm, which was spun out of SoftBank. AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
Marketwired - Wed Jan 06, 7:30AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that Michael Deperro has joined the Company as Vice President of Operations. In his role reporting directly to the Company's Chief Executive Officer, Mr. Deperro will oversee operations including manufacturing, engineering and facilities. ALKS: 48.95 (+0.91)
AntriaBio closes first USD2m in private placement
M2 - Fri Dec 11, 4:04AM CST
Biopharmaceutical corporation AntriaBio (Other OTC:ANTB) disclosed on Thursday the completion of the first USD2m under a planned USD15m private placement transaction.
AntriaBio Announces First Close of Private Placement Transaction
Marketwired - Thu Dec 10, 11:50AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it has closed the first $2 million of a planned $15 million private placement transaction (the "Transaction". AntriaBio will use the proceeds from the Transaction for general corporate purposes, including Phase 1 clinical studies for AB101, a once-weekly basal insulin for patients with type 1 and type 2 diabetes. AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
Marketwired - Tue Nov 17, 7:31AM CST
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/324,734 titled, "Solvent Extraction From Biodegradable Microparticles." The application covers the methods around solvent extraction and rinse in the manufacturing process for product candidates AB101 and AB301, as well as other internal and external potential pipeline therapies that use AntriaBio's proprietary microsphere drug delivery platform. A Notice of Allowance is a written notification from the USPTO that review of the patent application has completed and issuance of the patent is pending. AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
Marketwired - Wed Sep 16, 6:30AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced the addition of a new product candidate to its product development pipeline. AntriaBio names David F. Welch PhD to board
M2 - Tue Jun 30, 5:46AM CDT
AntriaBio Inc (OTC:ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced on Monday that it has appointed David F. Welch, PhD to the company's board of directors.
INFN: 11.32 (+0.56)
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
Marketwired - Mon Jun 29, 7:01AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today the appointment of David F. Welch, Ph.D., President and Co-Founder of Infinera Corporation (NASDAQ: INFN), to the Company's Board of Directors. Dr. Welch joins AntriaBio's Board as the Company prepares to conduct clinical studies for its lead product candidate, AB101, a potential once-weekly basal insulin in development for patients with type 1 and type 2 diabetes. INFN: 11.32 (+0.56)
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
Marketwired - Mon Jun 08, 6:30AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, released preclinical results for its lead product candidate, AB101, at the American Diabetes Association 75th Scientific Sessions® in Boston. The results demonstrated that AB101 has comparable in vitro pharmacology to native insulin, and in two animal species exhibited a prolonged subcutaneous insulin absorption profile, resulting in slow onset, peakless and sustained insulin levels with corresponding glucose reductions, without acute hypoglycemia caused by an insulin burst. These observations occurred at clinically relevant dose projections, demonstrating proof of concept of the potential for AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus. IPOs & Transactions Week in Review: May 18 - 22 plus "How-to" M&A Webinar Videos
PR Newswire - Tue May 26, 11:20AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Marketwired - Mon May 11, 7:02AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it will be presenting data for its lead product candidate, AB101, on Saturday, June 6, 2015 at the American Diabetes Association 75th Scientific Sessions® in Boston. The abstract, accepted for oral presentation, will include results from preclinical in vitro and in vivo pharmacology studies of AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Marketwired - Thu Jan 08, 6:35AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board. AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Marketwired - Wed Jan 07, 7:02AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment. 
